Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo) for advanced renal cell carcinoma (RCC) after anti–PD-(L)1 therapy: Open-label phase 3 LITESPARK-011 study.
R Motzer(Memorial Sloan Kettering Cancer Center), Manuela Schmidinger(Medical University of Vienna), Sammy Yuan(Merck & Co., Inc., Rahway, NJ, USA (United States)), Begoña P. Valderrama(Inserm), Rodolfo F. Perini(Merck & Co., Inc., Rahway, NJ, USA (United States)), Mauricio Burotto(Universidad de Los Andes, Chile), Cristina Suárez(Vall d'Hebron Hospital Universitari), Daniel Yick Chin Heng(University of Calgary), R. Iacovelli(Università Cattolica del Sacro Cuore), H. Westgeest(Amphia Ziekenhuis), Raymond S. McDermott(Cancer Trials Ireland), Se Hoon Park(Samsung Medical Center), John Haanen(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital), Ding Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Guillermo de Velasco(Research Institute Hospital 12 de Octubre), E. Verzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Hernan Cutuli, C. Porta(Azienda Universitaria Ospedaliera Consorziale - Policlinico Bari)
Cited by 4
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k